Debjani Sahni, MBBS
Clinical Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Dermatology

MBBS, King's College London
BSc, King's College London



Debjani Sahni, MBBS, Dermatology, specializes in the medical care of cutaneous oncology patients including cutaneous lymphoma, melanoma and high-risk non-melanoma skin cancer. She is the director of the multi-disciplinary cutaneous oncology program and the cutaneous oncology fellowship. Her clinical research focuses on the management of skin cancers in patients with limited access to healthcare. Dr. Sahni was named the G. Robert Baler Junior Faculty Professor of Dermatology, in recognition of her contributions to the department of dermatology. She is the recipient of several teaching awards as well as the Boston University Medical Group Excellence in Care Award.

Director
Boston University Chobanian & Avedisian School of Medicine
Dermatology
Cutaneous Oncology




EL-1007-01-01
03/16/2018 - 03/16/2021 (PI)
Elorac Inc


Cutaneous Oncology Fellowship
08/03/2012 - 06/30/2017 (PI)
Mallinckrodt LLC

Cutaneous Oncology Fellowship
07/03/2012 - 06/30/2016 (PI)
Genentech


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Sachedina D, Gibson F, Xia E, Walia A, Behara L, Fazelpour S, Mullins H, Francis J, Sahni D. Skin cancer in renal transplant recipients: outcomes from a safety net hospital in Boston. Int J Dermatol. 2024 Aug; 63(8):1048-1055.View Related Profiles. PMID: 38328999
     
  2. Sachedina D, Villa-Ruiz C, Brem C, Sahni D. Epidermolytic hyperkeratosis of the vulva: Case report and review of the literature. Skin Health Dis. 2024 Apr; 4(2):e325.View Related Profiles. PMID: 38577055; PMCID: PMC10988727; DOI: 10.1002/ski2.325;
     
  3. Kennamer B, Sachedina D, Nagrani N, Brem C, Sahni D. A Rare Case of Anetodermic Mycosis Fungoides. Acta Derm Venereol. 2023 Jul 03; 103:adv11926.View Related Profiles. PMID: 37395580; PMCID: PMC10326735; DOI: 10.2340/actadv.v103.11926;
     
  4. Kashani-Sabet M, Leachman SA, Stein JA, Arbiser JL, Berry EG, Celebi JT, Curiel-Lewandrowski C, Ferris LK, Grant-Kels JM, Grossman D, Kulkarni RP, Marchetti MA, Nelson KC, Polsky D, Seiverling EV, Swetter SM, Tsao H, Verdieck-Devlaeminck A, Wei ML, Bar A, Bartlett EK, Bolognia JL, Bowles TL, Cha KB, Chu EY, Hartman RI, Hawryluk EB, Jampel RM, Karapetyan L, Kheterpal M, Lawson DH, Leming PD, Liebman TN, Ming ME, Sahni D, Savory SA, Shaikh SS, Sober AJ, Sondak VK, Spaccarelli N, Usatine RP, Venna S, Kirkwood JM. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023 May 01; 159(5):545-553. PMID: 36920356; PMCID: PMC11225588; DOI: 10.1001/jamadermatol.2023.0127;
     
  5. Sanchez DP, Maymone MBC, McLean EO, Kennedy KF, Sahni D, Secemsky EA, Vashi NA. Racial and ethnic disparities in melanoma awareness: A cross-sectional survey. J Am Acad Dermatol. 2020 Oct; 83(4):1098-1103.View Related Profiles. PMID: 32380221
     
  6. Al-Haseni A, Vrable A, Qureshi MM, Mathews S, Pollock S, Truong MT, Sahni D. Survival outcomes of mucosal melanoma in the USA. Future Oncol. 2019 Dec; 15(34):3977-3986.View Related Profiles. PMID: 31724885
     
  7. Venkatesh S, Al-Haseni A, Sahni D. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab. BMJ Case Rep. 2019 Aug 02; 12(8). PMID: 31377718; PMCID: PMC6685369; DOI: 10.1136/bcr-2019-229915;
     
  8. Abbott JL, Qureshi MM, Truong MT, Sahni D. Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation. Melanoma Res. 2019 08; 29(4):413-419.View Related Profiles. PMID: 30383720
     
  9. Ho JD, Chung HJ, Ms Barron A, Ho DA, Sahni D, Browning JL, Bhawan J. Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring. Am J Dermatopathol. 2019 Jan; 41(1):16-28.View Related Profiles. PMID: 30320623
     
  10. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44. PMID: 30281145; PMCID: PMC6860362; DOI: 10.1002/cncr.31719;
     
Showing 10 of 29 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 29 publications over 11 distinct years, with a maximum of 6 publications in 2018

YearPublications
20101
20112
20131
20142
20163
20175
20186
20194
20201
20233
20241
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Cutaneous Oncology

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

609 Albany St (J Bldg)
Boston MA 02118
Google Map


Sahni's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department